TRAVATAN (travoprost), glaucoma eye drops

No clinical benefit demonstrated in paediatric patients, by comparison with its comparators, in the reduction of elevated intraocular pressure

• TRAVATAN now has Marketing Authorisation in the reduction of elevated intraocular pressure (IOP), from 2 months of age, in paediatric patients with intraocular hypertension or glaucoma.
• A study has demonstrated its non-inferiority relative to timolol after 12 weeks of treatment on the reduction of IOP in children.
• No long-term safety data are available.
• TRAVATAN contains excipients that may cause a skin reaction.